AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03825874 — intervention group
Intervention type: OTHER
Intervention: usual antibiotic treatment
Description: A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
Study NCT03024489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
Study NCT03024489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
Study NCT03024489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
Study NCT03024489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
Study NCT03024489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
Study NCT03024489 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
Study NCT00094770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin (MK0431)
Description: Sitagliptin 100 mg oral tablets of sitagliptin once daily.
Study NCT00094770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: glipizide
Description: Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
Study NCT05995288 — intervention group
Intervention type: DRUG
Intervention: Homeopathic Globule
Description: Homeopathic globules were administered after careful anamnesis
Study NCT02936427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: perineural infiltration of dexamethasone
Study NCT01230242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine Device
Description: levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
Study NCT03002584 — intervention group
Intervention type: OTHER
Intervention: completion of self-reported questionnaires
Description: Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale
Study NCT03943875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine, 2 dose efficacy
Description: Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
Study NCT03943875 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine, 3 doses standard timing
Description: Will be comparison group for 2 dose efficacy group.
Study NCT01601028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
Study NCT01601028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
Study NCT02909075 — intervention group
Intervention type: DEVICE
Intervention: PET/CT scans
Study NCT02909075 — intervention group
Intervention type: DEVICE
Intervention: MRI
Study NCT02234284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
Study NCT00381342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
Study NCT00381342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
Study NCT00381342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
Study NCT04659265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suspected diagnosis of a pre-treating physician
Description: Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
Study NCT04729036 — intervention group
Intervention type: PROCEDURE
Intervention: open reduction and internal fixation
Description: The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
Study NCT01394042 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Proxiscan device
Description: All patients will be imaged with the device
Study NCT00573430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 8 mg oral once daily dose
Study NCT00573430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 16 mg oral once daily dose
Study NCT00573430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 32mg
Description: 32 mg oral once daily dose
Study NCT01918007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy (AT)
Description: Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
Study NCT02838498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP Mechanical Simulator (EMS)
Description: Hands on EMS training
Study NCT02598843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment protocol
Description: Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy
Study NCT02598843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabilitation
Description: 4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced.
Study NCT03420690 — intervention group
Intervention type: OTHER
Intervention: satisfaction questionnaire after art therapy session
Description: After the administration of art therapy sessions (>1) and the death of patients (> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
Study NCT04174781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv Q3W D1
Study NCT04174781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
Study NCT01255527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
Study NCT00556452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine/Busulfan x 4
Description: Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days
Study NCT00556452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplant
Description: Peripheral blood stem cell transplant, after pre-conditioning drug treatment
Study NCT00556452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
Study NCT02560376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-exendin-4
Description: 68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
Study NCT01505621 — intervention group
Intervention type: OTHER
Intervention: L[ring-13C6]phenylalanine
Description: Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine
Study NCT00773812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecamylamine
Description: The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
Study NCT00773812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One pill is taken once daily.
Study NCT03391271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photobiomodulation therapy (PBMT)
Description: Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)
Study NCT03391271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham laser sessions
Description: • The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
Study NCT01068171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of footwear
Description: comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
Study NCT03450122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV
Study NCT03450122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00395226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: zinc sulfate 220 mg bis for 90 days
Study NCT00395226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid for 90 days
Study NCT02228382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 100 mg and 500 mg tablets, once daily dosage up to 4 years duration
Study NCT03450122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell-targeting Lentiviral Vector ID-LV305
Description: Given ID
Study NCT02421835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract
Description: 132 mg of oleuropein per day suspended in olive leaf extract 700 mg
Study NCT05946148 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin 10mg daily, as add-on to previous treatment regimen.
Study NCT05946148 — intervention group
Intervention type: DRUG
Intervention: Dulaglutide
Description: Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
Study NCT05946148 — intervention group
Intervention type: DRUG
Intervention: Control Rx
Description: Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
Study NCT02421835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 700 mg Maltodextrin per day
Study NCT03848832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P presented as an oral solution containing cannabidiol
Study NCT00510510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 100 µg
Description: Dry powder inhalation once a day for up to 28 days
Study NCT00510510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to NVA237 dry powder inhalation once a day for up to 28 days
Study NCT00510510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 200 µg
Description: Dry powder inhalation once a day for up to 28 days
Study NCT03643666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
Study NCT03848832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral solution
Study NCT03835806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastikon
Description: This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
Study NCT03643666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulphate
Description: patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
Study NCT03643666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
Study NCT03835806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocktape
Description: This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
Study NCT02509442 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion of direct electric stimulation
Description: During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
Study NCT02932254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
Study NCT02932254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
Study NCT02476526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Volume iso-osmolar non-ionic radio contrast medium
Description: Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
Study NCT02476526 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Acetylcysteine Inhalation
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
Study NCT02476526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine Inhalation
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
Study NCT02476526 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium Bicarbonate Solution
Description: Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
Study NCT02476526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Solution
Description: Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
Study NCT02476526 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 64-MDCT Scanning
Description: Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
Study NCT02476526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 64-MDCT Scanning
Description: Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
Study NCT03346564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ritual training program
Description: Ritual training program including education and demonstration
Study NCT03346564 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Study NCT02128152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso exoskeleton
Study NCT03958825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic hepatic sectionectomy
Description: patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
Study NCT03958825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left hepatic sectionectomy
Description: patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
Study NCT02787278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203 High dose
Description: High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
Study NCT01068171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen dressing with and without silver
Description: silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
Study NCT01436435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: Atherectomy
Study NCT02405832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
Study NCT02787278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203 Low dose
Description: Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
Study NCT02787278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study NCT04289545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan
Study NCT04289545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan
Study NCT02405832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge, with sweetener and citrus flavor, administered orally
Study NCT02613923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO! To Sleep
Description: Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
Study NCT02613923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep information
Description: Participants will receive weekly emails on the health benefits of sleep for 6 weeks
Study NCT02074501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training capacity in caregivers
Description: The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge.